As part of therapy, Trogarzo (ibalizumab) will be used by people who have experienced ineffective treatment with other ARVs. The new drug could be a solution for those who have been living with HIV for a long time and whose virus has acquired resistance to most of the available drugs.
A new study found that people with Trogarzo (Ibalizumab) were able to achieve a reduction in viral load 48 weeks before a condition when the virus was not detected by a test.
The new drug has proven to be safe and effective both in the third phase and in human studies. The most common side effects were diarrhea, headache, fatigue and nausea. However, all side effects were mild or moderate. In addition, Trogarzo is the first HIV drug to be taken not every day, but only once every two weeks.
The cause of resistance is incomplete suppression of virus mutations that occur in cases where the patient violates the treatment regimen. Multiple resistance is dangerous because at some stage it becomes difficult or impossible for the patient to find an effective alternative treatment regimen.